A Markov Model-Based Cost-Effectiveness Analysis Comparing Zanubrutinib to Ibrutinib for Treating Relapsed and Refractory Chronic Lymphocytic Leukemia.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH（2024）
关键词
Ibrutinib,zanubrutinib,cost-effectiveness,pharmacoeconomic evaluation,relapsed refractory chronic lymphocytic leukemia
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要